Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-13
2005-12-13
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S387000, C544S236000, C544S265000, C544S335000, C544S350000, C546S118000, C548S302700
Reexamination Certificate
active
06974815
ABSTRACT:
The present invention is directed to compounds having the formula (I):useful in treating inflammatory and immune diseases, in which K is O or S; Q is —C(═O)— or optionally substituted C1-4alkylene; Ar is optionally-substituted aryl or heteroaryl; J1, J2, J3, and Y are selected so that ring A is a five-to-six membered optionally-substituted cycloalkenyl or heterocyclo ring having 0 to 2 nitrogen heteroatoms; Z is N or C(R9); and R1, R2, R3and R9are as defined in the specification.
REFERENCES:
patent: 3930005 (1975-12-01), Wojnar et al.
patent: 4925853 (1990-05-01), Smith et al.
patent: 4925854 (1990-05-01), Schollkopf et al.
patent: 4933338 (1990-06-01), Constansa et al.
patent: 5021443 (1991-06-01), Bru-Magniez et al.
patent: 5124336 (1992-06-01), Bru-Magniez et al.
patent: 5128359 (1992-07-01), Bru-Magniez et al.
patent: 5182280 (1993-01-01), Cuberes-Altisent et al.
patent: 5716594 (1998-02-01), Elmaleh et al.
patent: 5922869 (1999-07-01), Werbitzky et al.
patent: 6350763 (2002-02-01), Kelly et al.
patent: 6436947 (2002-08-01), Borcherding et al.
patent: 6710064 (2004-03-01), Launay et al.
patent: 245637 (1987-11-01), None
patent: 352960 (1990-01-01), None
patent: WO 98/39303 (1998-09-01), None
patent: WO 99/11258 (1999-03-01), None
patent: WO 99/20617 (1999-04-01), None
patent: WO 99/20618 (1999-04-01), None
patent: WO 99/49856 (1999-10-01), None
patent: WO 00/21920 (2000-04-01), None
patent: WO 00/39081 (2000-07-01), None
patent: WO 00/48989 (2000-08-01), None
patent: WO 00/59880 (2000-10-01), None
patent: WO 01/06984 (2001-02-01), None
patent: WO 01/07044 (2001-02-01), None
patent: WO 01/07048 (2001-02-01), None
patent: WO 01/07052 (2001-02-01), None
patent: WO 01/07440 (2001-02-01), None
patent: WO 01/30781 (2001-05-01), None
patent: WO 01/51508 (2001-07-01), None
patent: WO 01/58853 (2001-08-01), None
patent: WO 02/02522 (2002-01-01), None
patent: WO 02/02539 (2002-01-01), None
patent: WO 02/28832 (2002-04-01), None
patent: WO 02/42294 (2002-05-01), None
patent: WO 02/44181 (2002-06-01), None
patent: WO 02/059114 (2002-08-01), None
Subramanian, P. and Dryhurst, G., “Isolation and characterization of 5-[3′-(7′,9′-dimethyluric acid)]-7,9-dimethyl-Δ3,4-isouric acid,” J. Electroanalytical Chem., vol. 262(1-2), pp. 281-287 (Apr. 1989) at p. 286 (Scheme 1, compound 3).
Anderson, M. and Siahaan, T., “Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors,” Peptides, vol. 24, pp. 487-501 (2003) at p. 489, col. 1, lines 28-44; and p. 493 (Table 1).
Yusuf-Makagiansar, H. et al, “Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a Therapeutic Approach to Inflammation and Autoimmune Diseases,” Medicinal Research Reviews, vol. 22(2), pp. 146-167 (2002) at p. 151, lines 29-48; p. 152, lines 11-14.
Whitcup, S., et al., “Blocking ICAM-1 (CD54) and LFA-1 (CD11a) Inhibits Experimental Allergic Conjunctivitis,” Clin. Immun., vol. 93(2), pp. 107-113 (Nov. 1999) at p. 112, line 41 to p. 113 line 2.
Zameer, A. and Hoffman, S., “Increased ICAM-1 and VCM-1 expression in the brains of autoimmune mice,” J. Neuroimmunology, vol. 142, pp. 67-74 (2003) at p. 72, col. 2, line 55 to p. 73, col. 1, line 10.
Apelt, J., et al., “Beta-Amyloid-associated expression of intercellular adhesion molecule-1 in brain cortical tissue of transgenic Tg2576 mice,” Neuroscience Letters, vol. 329, pp. 111-115 (2002) at p. 111, col. 1, lines 4-13; p. 114, col. 1, line 55.
Tanaka, Y., et al., “Intercellular Adhesion Molecule 1 Discriminates Functionally Different Populations of Human Osteoblasts,” J. Bone & Mineral Research, vol. 15(10), pp. 1912-1923 (Oct. 2000), at p. 1922.
Matsumoto, G., et al., “Essential Role of the Adhesion Receptor LFA-1 for T-Cell-Dependent Fulminant Hepatitis,” J. Immunology, vol. 169, pp. 7087-7096 (2002), at p. 7087, col. 2, lines 8-14; p. 7095, lines 25-49.
Mine, S., et al., “Oxidized low density lipoprotein-induced LFA-1-dependent adhesion and transendothelial migration of monocytes via the protein kinase C pathway,” Atherosclerosis, vol. 160, pp. 281-288 (2002), at p. 287, lines 41-54.
Kapsogeorgou, E., et al., “Activation of epithelial and myoepithelial cells in the salivary glands of patient with Sjogren's syndrome: high expression of ICAM-1 in biopsy specimens,” Clin. Exp. Immunology, vol. 124, pp. 126-133 (2001), p. 132, lines 20-25.
Mileski, W., et al., “Inhibition of CD18-dependent neutrophil adherence reduces organ injury after hemorrhagic shock in primates,” Surgery, vol. 108(2), pp. 206-212 (Aug. 1990) at p. 211, col. 2, lines 10-18.
Yokota, A., et al., “High Avidity State of Leukocyte Function Associated Antigen-1 on Rheumatoid Synovial Fluid T Lymphocytes,” J. Immun., vol. 55, pp. 4118-4124 (1995) at p. 4118, col. 2, lines 25-34; p. 4123, lines 55-59.
Kim, C., et al., “Acyclic Purine Phosphonate Analogues as Antiviral Agents: Synthesis and Structure-Activity Relationships,” J. Med. Chem., vol. 33(4) pp. 1207-1213 (1990) at p. 1209, col. 2, lines 1-31.
Mulligan, M., et al., “Role of Beta1, Beta-2 Integrins and ICAM-1 in Lung Injury after Deposition of IgG and IgA Immune Complexes,” J. Immunology, vol. 150(6), pp. 2407-2417 (Mar. 1993), at p. 2414, col. 2, lines 6-10 et seq.
Mulligan, M.,et al., “Compartmentalized Roles for Leukocytic Adhesion Molecules in Lung Inflammatory Injury,” J. Immunology, vol. 154; pp. 1350-1363 (1995) at p. 1351, col. 1, lines 7-15; p. 1362, col. 1, lines 3-26.
Rusznak, C., “Effect of Cigarette Smoke on the Permeability and IL-1-Beta and sICAM-1 Release from Cultured Human Bronchial Epithelial Cells,” Am. J. Respir. Cell Mol. Biol., vol. 23, pp. 530-536 (2000) at p. 535, col. 2, lines 12-25.
Floreani, A., et al., “Smoke and C5a Induce Airway Epithelial Intercellular Adhesion Molecule-1 and Cell Adhesion,” Am. J. Respir. Cell Mol. Biol., vol. 29, pp. 472-482 (2003) at p. 478, col. 1, line 56 et seq.
Noguera, A., et al., “Expression of Adhesion Molecules and G Proteins in Circulating Neutrophils in Chronic Obstructive Pulmonary Disease,” Am. J. Respir. Crit. Care Med., vol. 158, pp. 1664-1668 (1998) at p. 1664, col. 1, lines 1-10.
Takabatake, N., et al., “Impaired systemic cell-mediated immunity and increased susceptibility to acute respiratory tract infections in patients with COPD,” Respiratory Medicine, vol. 99, pp. 485-492 (2005) at p. 489, col. 2, lines 46-50.
Ding, Z., et al., “Relative Contribution of LFA-1 and Mac-1 to Neutrophil Adhesion and Migration,” Immunology, vol. 163, pp. 5029-5038 (1999) at p. 5037, col. 2, lines 2-5 and lines 8-21.
Andrew, D., et al., “Transendothelial migration and trafficking of leukocytes in LFA-1-deficient mice,” Eur. J. Immunol., vol. 28, pp. 1959-1969 (1998) at p. 1959, col. 1, line 2 to col. 2, line 13; p. 1966, col. 2, lines 42-53; & p. 1967, lines 1-2.
Hamaguchi, Y., et al., “Intercellular Adhesion Molecule-1 and L-Selectin Regulate Bleomycin-Induced Lung Fibrosis,” Am. J. Path., vol. 161(5) (Nov. 2002) at p. 1608, col. 1, lines 48-53; p. 1616, col. 2, lines 44-54.
Kuwano, K., et al., “Molecular Mechanisms of Pulmonary Fibrosis and Current Treatment,” Current Molecular Medicine, vol. 1(5), pp. 551-573 (2001) at p. 557, col. 2, lines 20-25.
Agusti, C., et al., “Goblet Cell Degranulation after Antigen Challenge in Sensitized Guinea Pigs,” Am. J. Respir. Crit. Care Med., vol. 156, pp. 1253-1258 (1998) at p. 1253, col. 1, lines 1-9; p. 1257, col. 1, lines 1-7.
Bhatia, M., “Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome,” Pathol., vol. 202, pp. 145-156 (2004) at p. 148, col. 2, lines 1-16.
Gauvreau, G., et al., “The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway
Dhar T G. Murali
Iwanowicz Edwin J.
Launay Michele
Maillet Magali Jeannine Blandine
Nicolai Eric Antoine
Bristol--Myers Squibb Company
Cerep SA
Duncan Laurelee A.
McKane Joseph K.
Paviglianiti Anthony J.
LandOfFree
Hexahydro-benzimidazolone compounds useful as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hexahydro-benzimidazolone compounds useful as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hexahydro-benzimidazolone compounds useful as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3516152